What does Medigen Biotechnology Corp. do?

Medigen Biotechnology Corp. (3176.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 3176.TWO's market cap?

Medigen Biotechnology Corp. (3176.TWO) has a market capitalization of approximately $5.54 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 3176.TWO pay a dividend?

No — Medigen Biotechnology Corp. (3176.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 3176.TWO profitable?

Medigen Biotechnology Corp. (3176.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

3176.TWO

Medigen Biotechnology Corp.

TWO·Biotechnology · Healthcare

NT$39.80NT$2.10+5.57%

Market capNT$5.54B·Market closed·Aug 26 5:30 AM UTC

Price Chart

NT$39.80+NT$2.10 (+5.57%)today

−33.89%CAGR −7.94%

Select date range

FromTo

Dec 31, 2007Aug 26, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

3176.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateFeb 26

Last Report DateDec 31

Reported vs Estimate−NT$0.82

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$1.32B

Net Income−NT$252.36M

Net Margin−19.2%

Operating Cash Flow−NT$44.62M

Capital ExpendituresNT$419.93M

Free Cash Flow−NT$464.55M

Return on Equity−17.1%

Return on Invested Capital−0.0%

Net CashNT$1.01B

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 3176.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 3176.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 3176.TWO and 80,000+ other tickers.

About Medigen Biotechnology Corp.

Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated to inventing therapies for liver diseases and various forms of cancer. Its product portfolio includes advanced cell therapies like MAGICELL-NK, which leverages natural killer cells, and MAGICELL-GDT, a T-cell-based treatment. A significant pipeline asset for Medigen is OBP-301. This therapeutic has completed Phase I clinical trials for combination therapy in esophageal cancer in Japan. It is currently being evaluated in ongoing Phase I trials in Japan, combining it with immune checkpoint inhibitors (ICIs) for…

CEO: Shi-Chung Chang
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 67
Website: www.medigen.com.tw

Peers

Peers Tab

6492.TWO

Senhwa Biosciences, Inc.

Cap

NT$3.2B

6794.TW

UnicoCell Biomed Co., Ltd.

Cap

NT$5.1B

6885.TWO

BRIM Biotechnology, Inc.

Cap

NT$2.8B

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 3176.TWO

What does Medigen Biotechnology Corp. do?: Medigen Biotechnology Corp. (3176.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 3176.TWO's market cap?: Medigen Biotechnology Corp. (3176.TWO) has a market capitalization of approximately $5.54 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 3176.TWO pay a dividend?: No — Medigen Biotechnology Corp. (3176.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 3176.TWO profitable?: Medigen Biotechnology Corp. (3176.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.